Cushman Elizabeth C. 4

What Happened

• Elizabeth C. Cushman, EVP, General Counsel and Secretary of Abbott Laboratories (ABT), received two awards on February 24, 2026: 15,031 performance-based restricted shares granted at $0.00 and a derivative award covering 61,964 shares granted at $0.00. The grants are awards (code A) — not open-market purchases or sales — so no cash changed hands at grant.

Key Details

• Transaction date: February 24, 2026; filing date: February 26, 2026 (filed timely).
• Awards: 15,031 restricted stock units/shares @ $0.00; 61,964-share derivative award @ $0.00.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote F1 (restricted shares): Performance-based restricted stock under Abbott’s 2017 Incentive Stock Program; 3-year term with no more than 1/3 vesting in any single year and vesting tied to meeting a minimum return-on-equity target. Award permits share withholding for taxes.
• Footnote F2 (derivative): Employee stock option granted under the 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option vests/exercises in annual increments of 20,654 on Feb 24, 2027; 20,655 on Feb 24, 2028; and 20,655 on Feb 24, 2029.
• Transaction codes: A = Award/Grant; the 61,964 entry is a derivative (option-style) grant, not an immediate exercise or sale.

Context

• Performance-based restricted stock typically vests over time only if company performance targets (here, ROE) are met; until vesting these shares are subject to forfeiture and cannot be sold. The option/derivative award is not exercised yet — it becomes exercisable in installments from 2027–2029 per the schedule above.
• Grants at $0.00 are standard for awards and do not represent a market purchase. These filings report compensation-related grants and should not be read as an immediate buy/sell signal.